72 related articles for article (PubMed ID: 8917400)
1. Prediction of the optimum clinical dosing schedule for menogaril from results with tumor-bearing mice.
Yoshida M; Kobunai T; Nakano K; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2869-73. PubMed ID: 8917400
[TBL] [Abstract][Full Text] [Related]
2. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
[TBL] [Abstract][Full Text] [Related]
4. [TUT-7 phase I clinical study. TUT-7 Study Group].
Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Nakao I; Ota K; Hattori T; Sugimachi K
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1125-33. PubMed ID: 9239166
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
6. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
7. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
8. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
10. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
Würthwein G; Boos J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
[TBL] [Abstract][Full Text] [Related]
11. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
12. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Zhao L; Ching LM; Kestell P; Baguley BC
Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
[TBL] [Abstract][Full Text] [Related]
13. Dose optimization of anthracyclines.
de Valeriola D
Anticancer Res; 1994; 14(6A):2307-13. PubMed ID: 7825964
[TBL] [Abstract][Full Text] [Related]
14. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
15. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
[TBL] [Abstract][Full Text] [Related]
17. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Weiss GR; Brown TD; Kuhn JG; Von Hoff DD; Earhart RH; Adams WJ; Brewer JE; Hosley JD; Kasunic DA
Invest New Drugs; 1993 Feb; 11(1):17-27. PubMed ID: 8349432
[TBL] [Abstract][Full Text] [Related]
19. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
